SCHEMBL30879550

SCHEMBL30879550

COC(=O)[C@@H]1C[C@H]1c1cccc([N+](=O)[O-])c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC9A1 P19634 1/20 0.62
TP53 P04637 1/20 0.54
IDO1 P14902 2/20 0.53
MAPT P10636 4/20 0.51
MEN1 O00255 3/20 0.51
KMT2A Q03164 3/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HIF1A Q16665 3/20 0.46
LMNA P02545 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2C9 P11712 2/20 0.46
CYP2C19 P33261 2/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
GPR55 Q9Y2T6 1/20 0.46
CYP2D6 P10635 1/20 0.46
TSHR P16473 1/20 0.46
NFKB1 P19838 1/20 0.46
THPO P40225 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30879548 1.00 SLC9A1 (0.62) SLC9A1TP53IDO1MAPTMEN1
SCHEMBL5780021 1.00 SLC9A1 (0.62) SLC9A1TP53IDO1MAPTMEN1
SCHEMBL21200226 0.91 SLC9A1 (0.54) SLC9A1TP53IDO1MAPTMEN1
SCHEMBL29867155 0.91 SLC9A1 (0.54) SLC9A1TP53IDO1MAPTMEN1
SCHEMBL29867619 0.86 SLC9A1 (0.58) SLC9A1TP53MAPTMEN1KMT2A
SCHEMBL28741885 0.86 SLC9A1 (0.58) SLC9A1TP53MAPTMEN1KMT2A
SCHEMBL28741883 0.86 SLC9A1 (0.58) SLC9A1TP53MAPTMEN1KMT2A
SCHEMBL5775091 0.83 SLC9A1 (0.67) SLC9A1TP53MAPTMEN1KMT2A
SCHEMBL15248884 0.83 IDO1 (0.54) TP53IDO1MAPTMEN1KMT2A
SCHEMBL13043598 0.83 IDO1 (0.54) TP53IDO1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199624-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CHDI FOUNDATION INC (US) 2024-06-20 US disclosed
WO-2024118607-A1 COMPOUNDS, COMPOSITIONS, AND METHODS CHDI FOUNDATION, INC. (US) 2024-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240199624-A1 COMPOUNDS, COMPOSITIONS, AND METHODS MSH2, KRAS, CHAMP1 SLC9A1 2775/4885TP53 14/4885IDO1 3263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.